Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized
(CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma
(NHL) at different dose levels.